The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovation

PharmacoEconomics

Volumn 22, Issue SUPPL. 2, 2004, Pages 81-86

  Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CELECOXIB; ROFECOXIB; TRIAZOLAM; TROGLITAZONE;

CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; DRUG WITHDRAWAL; HEALTH CARE ACCESS; HUMAN; PATIENT COMPLIANCE; PHARMACOECONOMICS; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; SIDE EFFECT;

COOPERATIVE BEHAVIOR; DELIVERY OF HEALTH CARE; DIFFUSION OF INNOVATION; ECONOMICS, PHARMACEUTICAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; PHARMACOEPIDEMIOLOGY;

EID: 8344237450     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422002-00009     Document Type: Conference Paper

References (17)

1. Marks H. The progress of experiment: science and therapeutic reform in the United States, 1900-1990. Cambridge (MA): The Cambridge University Press, 1997
2. Avorn J. Powerful medicines: the benefits, risks, and costs of prescription drugs. New York: Alfred A. Knopf, 2004
3. Hilts PJ. Protecting America's health: the FDA, business, and one hundred years of regulation. New York: Alfred A. Knopf, 2003
4. Morris CA, Avorn J. Internet marketing of herbal products. JAMA 2003; 290: 1505-9
5. Kessler RC, Berglund P, Dernier O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095-105
6. Solomon DH, Schneeweiss S, Glynn RJ, et al. Determinants of selective COX-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med 2003; 115: 715-20
7. Wang PS, Bohn RL, Glynn RJ, et al. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Amer J Psychiat 2001; 158: 892-8
8. Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med 1992; 327: 168-73
9. Solomon DH, van Houten L, Glynn RJ, et al. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med 2001; 161: 1897-902
10. Fedder DO, Koro CO, l'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation. 2002 Jan 15; 105(2): 152-6
11. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-61
12. Knight EL, Avorn J. Quality indicators for appropriate medication use in the care of the vulnerable elderly. Ann Intern Med 2001; 135: 703-10
13. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses. JAMA 2000; 283: 2116-21
14. Solomon DH, Schneeweiss S, Glynn RJ, et al. The relationship between selective COX-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004. In press
15. Gold M, Gold S, Weinstein M. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
16. Kalish S, Gurwitz JH, Krumholz H, et al. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med 1995; 10: 321-30
17. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med. 2002 Sep 26; 347 (13): 993-1000